natgillin/translations-raw huggingface dataset:
• It is important to be near a toilet with assistance available if necessary, since bowel movement may happen within 30 minutes after injection of the medicine.
• Pomembno je, da ste blizu stranišča in da je na voljo pomoč, če je to potrebno, ker lahko pride do iztrebljanja že v 30 minutah po vbrizganju zdravila.
• Safely throw away the Relistor pre-filled syringe after use (Step 4).
• Napolnjeno injekcijsko brizgo zdravila Relistor po uporabi varno odstranite (korak 4).
It treats constipation that is caused by medicines for moderate to severe pain called opioids (for example morphine or codeine).
Uporablja se za zdravljenje zaprtja, ki ga povzročajo zdravila za lajšanje zmernih do hudih bolečin, imenovana opioidi (na primer morfin ali kodein).
Relistor is indicated for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older.
Zdravilo Relistor je indicirano za zdravljenje konstipacije, povzročene z opioidi, kadar je odziv na odvajalno zdravljenje nezadosten, pri odraslih bolnikih, starih 18 let ali več.
What Relistor is and what it is used for
Kaj je zdravilo Relistor in za kaj ga uporabljamo
The effect on race could not be analysed because the study population was predominantly Caucasian (90 %).
Učinka na raso ni bilo mogoče analizirati, saj je bila večina študijske populacije belcev (90 %).
Data from clinical trials suggest treatment with methylnaltrexone bromide can result in the rapid onset (within 30 to 60 minutes on average) of a bowel movement.
Podatki iz kliničnih preskušanj kažejo, da zdravljenje z metilnaltreksonijevim bromidom lahko povzroči hiter začetek odvajanja blata (povprečno v 30 do 60 minutah).
Once you have drawn the medicine into the syringe, it must be used within 24 hours because Relistor is affected by light and may not work properly if it is left in the syringe for longer than 24 hours.
Ko izvlečete zdravilo v injekcijsko brizgo, ga morate porabiti v roku 24 ur, saj svetloba vpliva na zdravilo Relistor, ki morda ne bo pravilno učinkovalo, če ga boste v injekcijski brizgi pustili dlje kot 24 ur.
Do not insert it at an angle as the needle may bend or break.
Ne zabodite je pod kotom, ker bi se v tem primeru igla lahko zvila ali zlomila.
In the second week, a patient's assigned dose could be increased to 0.30 mg/kg if the patient had 2 or fewer rescue-free laxations up to day 8.
V drugem tednu se je lahko bolniku dodeljeni odmerek zvečal na 0,30 mg/kg, če je bolnik imel do 8. dneva največ 2 odvajanji brez rešilnega odvajala.
Do not inject into areas where the skin is tender, bruised, red, or hard.
Ne injicirajte si v predele, kjer je koža občutljiva, podpluta, pordela ali trda.
Hold the syringe at eye level so that you can see the dosing marks and make sure the tip of the needle is in the fluid all of the time.
Držite brizgo v višini oči, da boste lahko videli oznake za odmerjanje, in se prepričajte, da je konica igle povsem potopljena v tekočini.
Each of the methyl-6-naltrexol isomers has somewhat less antagonist activity than parent compound, and a low exposure in plasma of approximately 8 % of the drug-related materials.
Vsaka od izomer metil-6-naltreksola ima nekoliko manjšo antagonistično aktivnost od izhodne spojine in majhno izpostavljenost v plazmi, ki je približno 8 % snovi, povezanih z zdravilom.
This allows methylnaltrexone bromide to function as a peripherally acting mu-opioid antagonist in tissues such as the gastrointestinal tract, without impacting opioid-mediated analgesic effects on the central nervous system.
To metilnaltreksonijevemu bromidu omogoča, da deluje kot periferno delujoč mu-opioidni antagonist v tkivih, na primer v prebavilih, ne da bi vplival na analgetične učinke opioida na centralno živčevje.
Make sure not to touch the rubber stopper again.
Pazite, da se gumijastega zamaška ne dotaknete več.
Other medicines and Relistor
Druga zdravila in zdravilo Relistor
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti:
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with methylnaltrexone bromide should be made, taking into account the benefit of breast-feeding to the child and the benefit of methylnaltrexone bromide therapy to the woman.
Odločiti se je treba med nadaljevanjem/prenehanjem dojenja in nadaljevanjem/prekinitvijo zdravljenja z metilnaltreksonijevim bromidom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
There was no evidence of a differential effect of gender on safety or efficacy.
Dokazov o učinku zdravila glede na spol na varnost in učinkovitost ni bilo.
The use of methylnaltrexone bromide for treating opioid-induced constipation beyond 48 weeks has not been evaluated in clinical trials.
Uporabe metilnaltreksonijevega bromida za zdravljenje konstipacije, povzročene z opioidi, ki bi trajala dlje od 48 tednov, v kliničnih preskušanjih niso ocenili.
During the first week (days 1, 3, 5, 7), patients received either methylnaltrexone bromide 0.15 mg/kg or placebo.
V prvem tednu (1., 3., 5. in 7. dne) so bolniki prejemali bodisi po 0,15 mg/kg metilnaltreksonijevega bromida bodisi placebo.
Step 5: Disposing of supplies
Korak 5: Odstranjevanje
Opioid-induced constipation in adult patients with advanced illness Methylnaltrexone bromide treatment has not been studied in adult patients with advanced illness in clinical trials for longer than 4 months, and should therefore only be used for a limited period (see section 5.1).
Z opioidi povzročena konstipacija pri odraslih bolnikih z napredovalo boleznijo Zdravljenja z metilnaltreksonijevim bromidom niso preučili pri odraslih bolnikih v kliničnih preskušanjih, daljših od 4 mesecev, zato ga je treba uporabljati le za omejeno obdobje (glejte poglavje 5.1).
If you weigh less than 38 kg or more than 114 kg you should use Relistor vials because the correct dose cannot be accurately delivered with these pre-filled syringes.
Če tehtate manj kot 38 ali več kot 114 kg, uporabljajte viale zdravila Relistor, saj natančno dajanje ustreznega odmerka z napolnjenimi injekcijskimi brizgami ni mogoče.
Make sure that the dose prescribed by your doctor matches the dose on the pre-filled syringe label.
Prepričajte se, da je odmerek, ki vam ga je predpisal zdravnik, enak kot odmerek, naveden na nalepki napolnjene injekcijske brizge.
Methylnaltrexone bromide has minor influence on the ability to drive and use machines.
Metilnaltreksonijev bromid ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
If you are using the supplied injection syringe with retractable injection needle, DO NOT PUSH THE PLUNGER DOWN COMPLETELY.
Če uporabljate priloženo injekcijsko brizgo z vskočno injekcijsko iglo, NE POTISNITE BATA DO KONCA NAVZDOL.
What Relistor is and what it is used for What you need to know before you use Relistor How to use Relistor
Kaj je zdravilo Relistor in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Relistor Kako uporabljati zdravilo Relistor
INSTRUCTIONS FOR PREPARING AND GIVING AN INJECTION OF RELISTOR
NAVODILA ZA PRIPRAVO IN DAJANJE INJEKCIJE ZDRAVILA RELISTOR
Your doctor will determine your dose.
Odmerek vam bo določil zdravnik.
A study of healthy volunteers noted orthostatic hypotension associated with a dose of 0.64 mg/kg administered as an intravenous bolus.
V študiji na zdravih prostovoljcih so ugotovili ortostatsko hipotenzijo, povezano z odmerkom 0,64 mg/kg, danim v obliki intravenskega bolusa.
Slowly pull the plunger down to the 0.4 mL or 0.6 mL mark on the syringe or as advised, depending on the dose prescribed by your doctor, nurse or pharmacist.
Počasi izvlecite bat do oznake, ki označuje 0,4 ml, 0,6 ml ali drugo količino, odvisno od odmerka, ki vam ga je predpisal vaš zdravnik, medicinska sestra ali farmacevt.
Methylnaltrexone should not be used during pregnancy unless clearly necessary.
Metilnaltreksonijevega bromida ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Methylnaltrexone bromide is a selective antagonist of opioid binding at the mu-receptor.
Metilnaltreksonijev bromid je selektiven antagonist vezave opioidov na mu-receptor.
Use the other hand to gently pinch the cleaned area of skin and hold it firmly.
Z drugo roko na očiščenem predelu kože nežno naredite kožno gubo in jo čvrsto držite.
Gently tap the syringe to make any air bubbles rise to the top of the syringe; be sure that you still hold onto the vial and syringe.
Rahlo potrkajte po brizgi, da se bodo morebitni zračni mehurčki dvignili do vrha brizge; pazite, da boste še vedno držali vialo in brizgo.
Data from 133 (62 methylnaltrexone bromide, 71 placebo) patients were analysed.
Analizirali so podatke 133 bolnikov (62 z metilnaltreksonijevim bromidom, 71 s placebom).
Do not attempt to administer an injection until you are sure that you understand how to prepare and give an injection.
Ne poskušajte si dati injekcije, dokler niste prepričani, da veste, kako se zdravilo pripravi in injicira.
Studies in animals have shown reproductive toxicity at high doses (see section 5.3).
Študije na živalih so pri visokih odmerkih pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
Cardiac effects were observed in some non-clinical studies in canines (prolongation of action potentials in Purkinje fibers or prolongation of the QTc interval).
V nekaterih predkliničnih raziskavah na psih so ugotavljali učinke na srce (podaljšanje akcijskih potencialov v Purkynjevih vlaknih ali podaljšanje intervala QTc).
NN:
NN: {številka}
Severe renal impairment decreased the renal clearance of methylnaltrexone bromide by 8- to 9-fold; however, this resulted in only a 2-fold increase in total methylnaltrexone bromide exposure (AUC).
Težka ledvična okvara je zmanjšala ledvični očistek metilnaltreksonijevega bromida za 8- do 9-krat; vendar se je pri tem celotna izpostavljenost metilnaltreksonijevemu bromidu (AUC) samo podvojila.
UNIQUE IDENTIFIER - HUMAN READABLE DATA PC:
EDINSTVENA OZNAKA - V BERLJIVI OBLIKI PC: {številka}
Gather the supplies you will need for your injection:
Pripravite si vse, kar boste potrebovali za injiciranje:
Pack sizes of 4, 7, 8 and 10 pre-filled syringes.
Pakiranja po 4, 7, 8 in 10 napolnjenih injekcijskih brizg.
If you forget to use Relistor
Če ste pozabili uporabiti zdravilo Relistor
• If you have severe stomach symptoms which continue or get worse, contact your doctor immediately because these could be symptoms of a hole developing in the bowel wall (intestinal perforation).
• Če se pri vas pojavijo hude trebušne težave, ki se nadaljujejo ali se slabšajo, se takoj posvetujte s svojim zdravnikom, saj bi lahko ti znaki kazali na predrtje stene črevesja (perforacijo črevesja).
After withdrawal in the injection syringe:
Po potegu v injekcijsko brizgo:
Therefore, Relistor should only be administered with caution in these patients.
Zato moramo zdravilo Relistor pri teh bolnikih uporabljati zelo previdno.
If you have used more of this medicine than you should (either by injecting too much on a single occasion or by using more than one injection in 24 hours), you may feel dizzy when standing up, so talk to a doctor or pharmacist immediately.
Če ste uporabili večji odmerek zdravila Relistor, kot bi smeli Če ste uporabili več tega zdravila, kot bi smeli (bodisi z enkratnim vbrizganjem prevelikega odmerka bodisi tako, da ste si dali več kot eno injekcijo v 24 urah), ste lahko med vstajanjem omotični, zato se takoj posvetujte s svojim zdravnikom ali farmacevtom.
Due to the safety design of the syringe, a small air bubble may be resistant to removal.
Zaradi varnostne zasnove injekcijske brizge majhnih zračnih mehurčkov morda ne boste mogli povsem odstraniti.
Look at the pre-filled syringe.
Oglejte si napolnjeno injekcijsko brizgo.
• Please also talk to your doctor if you have a colostomy, a tube in your abdomen (peritoneal catheter), or suffer from diverticular disease or faecal impaction as this medicine should be used carefully in these circumstances.
• Pogovorite se s svojim zdravnikom tudi, če imate kolostomijo, cevko v trebuhu (peritonealni kateter) ali če trpite za divertikularno boleznijo ali impaktacijo blata, saj je treba to zdravilo v teh primerih uporabljati previdno.
It is recommended to rotate injection sites.
Priporočljivo je menjavati mesta injiciranja.
In vitro metabolism studies suggest that methylnaltrexone bromide does not inhibit the activity of CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 or CYP3A4, while it is a weak inhibitor of the metabolism of a model CYP2D6 substrate.
Študije presnove in vitro kažejo, da metilnaltreksonijev bromid ne inhibira aktivnosti CYP1A2, CYP2E1, CYP2B6, CYP2A6, CYP2C9, CYP2C19 in CYP3A4, je pa šibak inhibitor presnove modelnega substrata CYP2D6.
• If you feel sick, vomit, shiver, sweat, have belly pain and/or feel a fast heart beat shortly after taking Relistor talk to your doctor
• Če vam je slabo, bruhate, imate mrzlico, se znojite, vas boli trebuh in/ali občutite hiter srčni utrip kmalu po tem, ko ste vzeli zdravilo Relistor, se posvetujte z zdravnikom.
The adverse reactions are classified as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni kot: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000) in neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
Do not touch this area again before giving the injection.
Nato se ne dotikajte več tega predela, dokler ne boste dali injekcije.
These patients should use Relistor vials and not the pre-filled syringe.
Ti bolniki morajo uporabljati viale zdravila Relistor, ne napolnjenih injekcijskih brizg.
Always make sure you have the correct dose in the syringe.
Vedno se prepričajte, da ste v injekcijsko brizgo izvlekli pravilen odmerek zdravila.
The rate of laxation response was maintained throughout the extension studies for those patients who continued treatment.
Odzivnost na odvajalo je pri bolnikih, ki so nadaljevali zdravljenje, vztrajala ves čas podaljšanih študij.
In adult and juvenile dogs given methylnaltrexone bromide at 20 mg/kg/day, clinical signs indicative of CNS toxicity and prolongation of QTc interval were observed.
Pri odraslih psih in mladičih, ko so prejemali metilnaltreksonijev bromid v odmerkih 20 mg/kg/dan, so opazili klinične znake, značilne za toksičnost za osrednji živčni sistem, in podaljšanje intervala QTc.
Slowly push the plunger up until all air bubbles are removed.
Počasi potisnite bat navzgor, dokler ne boste odstranili vseh zračnih mehurčkov.
SN:
SN: {številka}
In these patients, the treatment with usual laxatives should be stopped when commencing treatment with Relistor (see section 5.1).
Pri teh bolnikih je treba zdravljenje z običajnimi odvajalnimi zdravili pri uvedbi zdravljenja z zdravilom Relistor ustaviti (glejte poglavje 5.1).
The difference between methylnaltrexone bromide 12 mg once daily and placebo of 1.6 RFBMs per week is statistically significant (p < 0.001) and clinically meaningful.
Razlika med metilnaltreksonijevim bromidom 12 mg enkrat na dan in placebom, ki je 1,6 iztrebljanja brez rešilnega odvajala na teden, je statistično značilna (p < 0,001) in klinično pomembna.
Therefore, Relistor should not be used for treatment of patients with constipation not related to opioid use.
Zato zdravila Relistor ne bi smeli uporabljati za zdravljenje bolnikov s konstipacijo, ki ni povezana z uporabo opioidov.
Keep the needle attached to the syringe.
Igla naj ostane pritrjena na brizgo.
There may be a little bleeding at the injection site.
Na mestu injiciranja se lahko pojavi par kapljic krvi.
Push the full length of the needle into the skin at a slight angle (45 degrees) with a quick, short motion.
S hitrim in kratkim gibom celotno dolžino igle zabodite v kožo pod rahlim kotom (45 stopinj).
There are no adequate data with the use of methylnaltrexone bromide in pregnant women.
Ni zadostnih podatkov o uporabi metilnaltreksonijevega bromida pri nosečnicah.
• Do not use a Relistor pre-filled syringe more than one time, even if there is medicine in the syringe.
• Napolnjeno injekcijsko brizgo zdravila Relistor uporabite samo enkrat tudi, če je v njej ostalo zdravilo.
Insert the needle straight down into the centre of the vial stopper.
Zabodite iglo naravnost navzdol v sredino zamaška viale.
Make sure you stop pushing the plunger when you feel resistance.
Pazite, da boste takrat, ko boste začutili upor, prenehali potiskati bat.
If you push solution back into the vial, slowly pull back the plunger to draw the correct amount of solution back into the syringe.
Če pri tem potisnete raztopino nazaj v vialo, počasi povlecite bat nazaj, da potegnete pravilno količino raztopine nazaj v brizgo.
N-demethylation of methylnaltrexone bromide to produce naltrexone is not significant, accounting for 0.06 % of the administered dose.
N-demetilacija metilnaltreksonijevega bromida v naltreksonij ni pomembna, saj predstavlja samo 0,06 % danega odmerka.
No studies were performed in patients with end-stage renal impairment requiring dialysis.
Pri bolnikih z okvaro ledvic v končnem stadiju, pri katerih bi bila potrebna dializa, niso opravili nikakršnih študij.
If needed, you may cover the injection site with a plaster.
Če je treba, ga lahko pokrijete z obližem.
In a study comparing single and multiple-dose pharmacokinetic profiles of intravenous methylnaltrexone bromide at a dose of 24 mg between healthy, young (18 to 45 years of age n = 10) and elderly (65 years of age and over n = 10) subjects, the effect of age on exposure to methylnaltrexone bromide was found to be minor.
V študiji, v kateri so primerjali farmakokinetične profile enkratnih in večkratnih 24-miligramskih intravenskih odmerkov metilnaltreksonijevega bromida pri zdravih mladih (starost 18 do 45 let, n = 10) in starejših (starost 65 let in več, n = 10) preiskovancih, so ugotovili, da je vpliv starosti na izpostavljenost metilnaltreksonijevemu bromidu manj pomemben.
There was no evidence of teratogenicity in rats or rabbits.
Pri podganah in zajcih ni bilo znakov teratogenosti.
Relistor can be injected without regard to food.
Zdravilo Relistor lahko injiciramo ne glede na obroke hrane.
• Abdominal pain (stomach ache)
abdominalna bolečina (bolečina v trebuhu),
Methylnaltrexone bromide does not affect the pharmacokinetics of medicinal products metabolised by cytochrome P450 (CYP) isozymes.
Metilnaltreksonijev bromid ne vpliva na farmakokinetiko zdravil, ki jih presnavljajo izocimi s citokromom P450 (CYP).
If you experience any of these side effects, which are either severe or will not go away, you should talk to your doctor:
Če se pri vas pojavi kateri od teh neželenih učinkov, in je resen ali ne mine, se posvetujte s svojim zdravnikom:
Patients had a history of chronic non-cancer pain and were taking opioids with stable doses of at least 50 mg of oral morphine equivalents per day.
Bolniki so imeli anamnezo kronične bolečine, ki ni posledica raka, in so jemali stabilne odmerke opioidov, ki so ustrezali vsaj 50 mg peroralnega morfina na dan. Bolniki so imeli z opioidi povzročeno konstipacijo
Make sure you have set aside a proper amount of time to complete the injection.
Poskrbite, da boste imeli na voljo dovolj časa za injiciranje zdravila.
Following intravenous injection of methylnaltrexone bromide, juvenile rats were found to be more sensitive than adult rats to methylnaltrexone-related toxicity.
Po intravenskem injiciranju metilnaltreksonijevega bromida so ugotovili, da so bili mladiči podgan v primerjavi z odraslimi podganami občutljivejši na toksičnost, povezano z metilnaltreksonom.
Ask your pharmacist how to thow away medicines that you no longer use.
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Methylnaltrexone bromide is absorbed rapidly, with peak concentrations (Cmax) achieved at approximately 0.5 hours following subcutaneous administration.
Metilnaltreksonijev bromid se absorbira hitro, maksimalna koncentracija (Cmax) se doseže približno pol ure po subkutanem odmerku zdravila.
Methylnaltrexone bromide is eliminated primarily as the unchanged active substance.
Metilnaltreksonijev bromid se odstranjuje iz telesa predvsem kot nespremenjena zdravilna učinkovina.
In a clinical drug interaction study in healthy adult male subjects, a subcutaneous dose of 0.3 mg/kg of methylnaltrexone bromide did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate.
V klinični študiji medsebojnega delovanja zdravil pri zdravih odraslih moških subkutan odmerek 0,3 mg/kg metilnaltreksonijevega bromida ni signifikantno vplival na presnovo dekstrometorfana, ki je substrat CYP2D6.
The renal clearance of methylnaltrexone bromide was reduced following multiple-dose administration of cimetidine (from 31 L/h to 18 L/h).
Ledvični očistek metilnaltreksonijevega bromida se je po uporabi večkratnih odmerkov cimetidina zmanjšal (z 31 l/uro na 18 l/uro).
For patients with long-term pain (except patients receiving supportive care for advanced illness), fill the syringe to the 0.6 mL mark for 12 mg of Relistor.
Za bolnike z dolgotrajno bolečino (razen za bolnike, ki prejemajo podporno nego za napredovalo bolezen), injekcijsko brizgo napolnite do oznake 0,6 ml za 12 mg zdravila Relistor.
Packs of more than one vial contain inner cartons consisting of: one vial, one 1 mL injection syringe with retractable injection needle, and two alcohol swabs.
Pakiranja, ki vsebujejo več kot eno vialo, vsebujejo notranje škatle, ki jih sestavljajo: ena viala, ena 1-mililitrska injekcijska brizga z vskočno injekcijsko iglo in dva alkoholna zloženca.
Clean the injection site with an alcohol swab and let it dry.
Z alkoholnim zložencem obrišite mesto injiciranja in pustite, da se posuši.
Study 301 compared methylnaltrexone bromide given as a single, double-blind, subcutaneous dose of 0.15 mg/kg, or 0.3 mg/kg versus placebo.
V študiji 301 so primerjali metilnaltreksonijev bromid, dan kot enkraten, dvojno slep subkutan odmerek 0,15 mg/kg, ali 0,3 mg/kg s placebom.
Severity and worsening symptoms Patients should be advised to promptly report severe, persistent, and/or worsening symptoms.
Bolnikom je treba svetovati, naj hude ali perzistentne simptome oziroma njihovo poslabšanje, čim prej sporočijo.
Animal studies have shown excretion of methylnaltrexone bromide in breast milk.
Študije na živalih so pokazale izločanje metilnaltreksonijevega bromida v mleko.
Are you familiar with the technique of self injection or have you discussed this with your doctor (or nurse or pharmacist)?
Ste seznanjeni s tehniko samoinjiciranja oziroma ste se o tem pogovorili s svojim zdravnikom
Release your thumb from the plunger to allow the protective sleeve to cover the needle.
Odmaknite palec z bata, da zaščitni etui prekrije iglo.
Subcutaneous injections of Relistor at 150 mg/kg/day decreased fertility in rats.
Subkutano injiciranje zdravila Relistor v odmerkih 150 mg/kg/dan je pri podganah zmanjšalo plodnost.
As a quaternary amine, the ability of methylnaltrexone bromide to cross the blood-brain barrier is restricted.
Ker je metilnaltreksonijev bromid kvarterni amin, je njegova sposobnost prehajanja krvno-možganske pregrade omejena.
Carefully pull back the plunger to correct level on syringe (e.g. 0.4 mL if you have been prescribed 8 mg)
Previdno povlecite bat nazaj na pravilno raven na injekcijski brizgi (npr. 0,4 ml, če vam je bil predpisan odmerek 8 mg)
To prepare the area of skin where Relistor is to be injected, wipe the injection site with an alcohol swab.
Pripravite predel kože, kamor boste injicirali zdravilo Relistor, tako da mesto injiciranja obrišete z alkoholnim zložencem.
The mean methylnaltrexone bromide exposure at 0.15 mg/kg over a weight range of 38 to 114 kg was 179 (range = 139-240) ng•h/mL.
Povprečna izpostavljenost metilnaltreksonijevemu bromidu pri odmerku 0,15 mg/kg pri telesni masi med 38 do 114 kg je bila 179 (razpon = 139-240) ng•h/ml.